Michael R Hayden - Net Worth and Insider Trading
Michael R Hayden Net Worth
The estimated net worth of Michael R Hayden is at least $18 Million dollars as of 2024-12-03. Michael R Hayden is the Director of Xenon Pharmaceuticals Inc and owns about 267,421 shares of Xenon Pharmaceuticals Inc (XENE) stock worth over $11 Million. Michael R Hayden is the Director of AbCellera Biologics Inc and owns about 1,441,642 shares of AbCellera Biologics Inc (ABCL) stock worth over $4 Million. Michael R Hayden is also the Director of 89bio Inc and owns about 246,420 shares of 89bio Inc (ETNB) stock worth over $2 Million. Details can be seen in Michael R Hayden's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Michael R Hayden has not made any transactions after 2023-09-22 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Michael R Hayden
Michael R Hayden Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Michael R Hayden owns 5 companies in total, including Ionis Pharmaceuticals Inc (IONS) , 89bio Inc (ETNB) , and Xenon Pharmaceuticals Inc (XENE) among others .
Click here to see the complete history of Michael R Hayden’s form 4 insider trades.
Insider Ownership Summary of Michael R Hayden
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| IONS | Ionis Pharmaceuticals Inc | 2018-09-20 | director |
| ETNB | 89bio Inc | 2023-03-28 | director |
| XENE | Xenon Pharmaceuticals Inc | 2019-03-11 | director |
 | | 2021-01-01 | director |
| | 2023-09-22 | director |
Michael R Hayden Latest Holdings Summary
Michael R Hayden currently owns a total of 3 stocks. Among these stocks, Michael R Hayden owns 267,421 shares of Xenon Pharmaceuticals Inc (XENE) as of August 14, 2017, with a value of $11 Million and a weighting of 63.9%. Michael R Hayden owns 1,441,642 shares of AbCellera Biologics Inc (ABCL) as of September 22, 2023, with a value of $4 Million and a weighting of 23.87%. Michael R Hayden also owns 246,420 shares of 89bio Inc (ETNB) as of March 28, 2023, with a value of $2 Million and a weighting of 12.24%.
Latest Holdings of Michael R Hayden
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| XENE | Xenon Pharmaceuticals Inc | 2017-08-14 | 267,421 | 42.00 | 11,231,682 |
| ABCL | AbCellera Biologics Inc | 2023-09-22 | 1,441,642 | 2.91 | 4,195,178 |
| ETNB | 89bio Inc | 2023-03-28 | 246,420 | 8.73 | 2,151,247 |
Holding Weightings of Michael R Hayden
Michael R Hayden Form 4 Trading Tracker
According to the SEC Form 4 filings, Michael R Hayden has made a total of 0 transactions in Xenon Pharmaceuticals Inc (XENE) over the past 5 years. The most-recent trade in Xenon Pharmaceuticals Inc is the acquisition of 15,000 shares on August 14, 2017, which cost Michael R Hayden around $41,250.
According to the SEC Form 4 filings, Michael R Hayden has made a total of 4 transactions in AbCellera Biologics Inc (ABCL) over the past 5 years, including 3 buys and 1 sells. The most-recent trade in AbCellera Biologics Inc is the acquisition of 20,000 shares on September 22, 2023, which cost Michael R Hayden around $98,200.
According to the SEC Form 4 filings, Michael R Hayden has made a total of 1 transactions in 89bio Inc (ETNB) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in 89bio Inc is the acquisition of 87,788 shares on March 28, 2023, which cost Michael R Hayden around $1 Million.
Insider Trading History of Michael R Hayden
- 1
Michael R Hayden Trading Performance
GuruFocus tracks the stock performance after each of Michael R Hayden's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Michael R Hayden is 0.22%. GuruFocus also compares Michael R Hayden's trading performance to market benchmark return within the same time period. The performance of stocks bought by Michael R Hayden within 3 months outperforms 3 times out of 6 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Michael R Hayden's insider trading performs compared to the benchmark.
Performance of Michael R Hayden
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 5.19 | | | | | |
| Relative Return to S&P 500(%) | 4.05 | | | | | |
Michael R Hayden Ownership Network
Michael R Hayden Owned Company Details
What does Ionis Pharmaceuticals Inc do?
Who are the key executives at Ionis Pharmaceuticals Inc?
Michael R Hayden is the director of Ionis Pharmaceuticals Inc. Other key executives at Ionis Pharmaceuticals Inc include SVP & Research Eric Swayze , director & Senior Vice President Brett P Monia , and Senior Vice President Richard S Geary .
Ionis Pharmaceuticals Inc (IONS) Insider Trades Summary
Over the past 18 months, Michael R Hayden made no insider transaction in Ionis Pharmaceuticals Inc (IONS). Other recent insider transactions involving Ionis Pharmaceuticals Inc (IONS) include a net sale of 183,096 shares made by Brett P Monia , a net sale of 49,324 shares made by Eric Swayze , and a net sale of 35,600 shares made by Richard S Geary .
In summary, during the past 3 months, insiders sold 21,385 shares of Ionis Pharmaceuticals Inc (IONS) in total and bought 0 shares, with a net sale of 21,385 shares. During the past 18 months, 629,070 shares of Ionis Pharmaceuticals Inc (IONS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 629,070 shares.
Ionis Pharmaceuticals Inc (IONS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Ionis Pharmaceuticals Inc Insider Transactions
Michael R Hayden Mailing Address
Above is the net worth, insider trading, and ownership report for Michael R Hayden. You might contact Michael R Hayden via mailing address: C/o Aspreva Pharmaceuticals Corporation, 1203-4464 Markham Street, Victoria A1 V8z 7x8.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
